Evidence map›Paper›PMID 28371318›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.

Iñaki Sanz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. SLE: reconciling heterogeneity.Lupus science & medicine · 2019
    Article
  4. Article
  5. DNA as a self-antigen: nature and regulation.Current opinion in immunology · 2018
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Iñaki SanzEmory University School of Medicine, Atlanta, Georgia.

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI JEREMY M. BOSS · 2014 to 2026
$76.6M
Regulation of Pathogenic Plasma Cells in Human SLEP01AI125180 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2016 to 2026
$28.2M
Translational Research Project Effector and Regulatory B cells in SLEU19AI056390 · NIAID · UNIVERSITY OF ROCHESTER · PI LOONEY, RICHARD JOHN · 2003 to 2013
$8.9M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
A Model System for the Study of Human B-cell ToleranceR01AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2003 to 2007
$1.6M
NIAID NIH HHS P01 AI125180NIAID NIH HHS R01 AI049660NIAID NIH HHS R37 AI049660NIAID NIH HHS U19 AI056390NIAID NIH HHS U19 AI110483
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell- and Tissue-Based TherapyAntibodies, Monoclonal, HumanizedBiomedical ResearchCalcineurin InhibitorsClinical Trials as TopicCytokinesHistone Deacetylase InhibitorsHumansImmunosuppressive AgentsInflammasomesLupus Erythematosus, SystemicLymphocyte DepletionMolecular Targeted TherapyProgrammed Cell Death 1 ReceptorQuinolonesRheumatologyAntibodies, Monoclonal, HumanizedbelimumabCalcineurin InhibitorsCytokinesepratuzumabHistone Deacetylase InhibitorsImmunosuppressive AgentsInflammasomeslaquinimodPDCD1 protein, humanProgrammed Cell Death 1 ReceptorQuinolones

Identifiers

PMID28371318
PMCPMC5529217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.